Search results for "Marrow fibrosis"

showing 3 items of 3 documents

Morphometric Study of the Bone Marrow in Polycythemia Vera Following Interferon-Alpha Therapy

1993

Bone marrow cellularity and extent of fibrotic change were determined in nineteen patients with polycythemia vera, treated with interferon-alpha (IFN) for 1 year. The cellularity was evaluated with an interactive semiautomatic method using Leitz TAS plus microscope: in particular, number and size of megakaryocytes were evaluated after immunostaining with Y2/51 (CD 61); reticulin content was studied by light microscope with a semiquantitative method. Before IFN therapy mean cellularity was 80.5% (+/- 13.7). After 6 and 12 months mean cellularity was 75.4% and 68.4% respectively. Six months after cessation of IFN therapy the cellularity was 69.1%. A decrease of the number, density and morphom…

AdultMalePathologymedicine.medical_specialtyAlpha interferonCell CountPathology and Forensic MedicinePolycythemia veraBone MarrowFibrosishemic and lymphatic diseasesmedicineHumansMyelofibrosisPolycythemia VeraAgedAged 80 and overbusiness.industryInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseBone marrow cellularitymedicine.anatomical_structurePrimary MyelofibrosisMarrow fibrosisFemaleBone marrowbusinessMegakaryocytesImmunostainingPathology - Research and Practice
researchProduct

Bone marrow fibrosis and diagnosis of essential thrombocythemia

2009

However, there are serious issues to beraisedconcerningtheauthors’analysisoftheclinicaldata,thecriteriausedtodiagnoseET,andthequantificationoffibrosis.Altogethertheauthors compared a heterogenous patient database, which included311 patients evaluated for presenting features, 299 for response totherapy,361forcomplicationrates,97forprogressionoffibrosis,andfour for reversal of BM fibrosis, so no single cohort with consistentfeatures was described throughout the study of 361 patients. Forexample, for the analysis of progression of fibrosis, only 97 (12%) oftheoriginal809patientsenteredintheUK-PT1trial

Cancer Researchmedicine.medical_specialtyPathologyessential thrombocythemiabusiness.industryEssential thrombocythemiaMEDLINEBone marrow fibrosismedicine.diseasemyeloproliferative neoplasmsOncologyInternal medicineCohortMedicinePatient databasebusinessBone marrow fibrosi
researchProduct

A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.

2014

7022^ Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by dysregulation of the Janus kinase (JAK) pathway resulting in bone marrow fibrosis, splenomegaly, and debilitat...

Cancer ResearchRuxolitinibPathologymedicine.medical_specialtybusiness.industryBone marrow fibrosismedicine.diseasechemistry.chemical_compoundDose findingOncologychemistryPanobinostatCancer researchMedicineIn patientbusinessJanus kinaseMyelofibrosisMyeloproliferative neoplasmmedicine.drugJournal of Clinical Oncology
researchProduct